These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 24023337)

  • 1. Microsatellite instability analysis for the screening of synchronous endometrial and ovarian cancer in Lynch syndrome.
    Bats AS; Roussel H; Narjoz C; Le Frere-Belda MA; Chamming's F; Blons H; Laurent-Puig P; Lecuru F
    Anticancer Res; 2013 Sep; 33(9):3977-81. PubMed ID: 24023337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients.
    Hampel H; Frankel W; Panescu J; Lockman J; Sotamaa K; Fix D; Comeras I; La Jeunesse J; Nakagawa H; Westman JA; Prior TW; Clendenning M; Penzone P; Lombardi J; Dunn P; Cohn DE; Copeland L; Eaton L; Fowler J; Lewandowski G; Vaccarello L; Bell J; Reid G; de la Chapelle A
    Cancer Res; 2006 Aug; 66(15):7810-7. PubMed ID: 16885385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pseudomyxoma peritonei of a mature ovarian teratoma caused by mismatch repair deficiency in a patient with Lynch syndrome: a case report.
    Gohda Y; Noguchi R; Horie T; Igari T; Nakamura H; Ohta Y; Yamaguchi K; Ikenoue T; Hatakeyama S; Yusa N; Furukawa Y; Yano H
    BMC Med Genet; 2016 Dec; 17(1):94. PubMed ID: 27938333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.
    Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM
    Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor site discordance in mismatch repair deficiency in synchronous endometrial and ovarian cancers.
    Kim SR; Tone A; Kim R; Cesari M; Clarke B; Eiriksson L; Hart T; Aronson M; Holter S; Lytwyn A; Maganti M; Oldfield L; Gallinger S; Bernardini MQ; Oza AM; Djordjevic B; Lerner-Ellis J; Van de Laar E; Vicus D; Pugh TJ; Pollett A; Ferguson SE
    Int J Gynecol Cancer; 2020 Dec; 30(12):1951-1958. PubMed ID: 33082239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor Screening and DNA Testing in the Diagnosis of Lynch Syndrome.
    Usha L; Dewdney SB; Buckingham LE
    JAMA; 2016 Jul; 316(1):93-4. PubMed ID: 27380347
    [No Abstract]   [Full Text] [Related]  

  • 7. Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability.
    Aysal A; Karnezis A; Medhi I; Grenert JP; Zaloudek CJ; Rabban JT
    Am J Surg Pathol; 2012 Feb; 36(2):163-72. PubMed ID: 22189970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simplified identification of Lynch syndrome: a prospective, multicenter study.
    Bonnet D; Selves J; Toulas C; Danjoux M; Duffas JP; Portier G; Kirzin S; Ghouti L; Carrère N; Suc B; Alric L; Barange K; Buscail L; Chaubard T; Imani K; Guimbaud R
    Dig Liver Dis; 2012 Jun; 44(6):515-22. PubMed ID: 22480969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer.
    Pérez-Carbonell L; Ruiz-Ponte C; Guarinos C; Alenda C; Payá A; Brea A; Egoavil CM; Castillejo A; Barberá VM; Bessa X; Xicola RM; Rodríguez-Soler M; Sánchez-Fortún C; Acame N; Castellví-Bel S; Piñol V; Balaguer F; Bujanda L; De-Castro ML; Llor X; Andreu M; Carracedo A; Soto JL; Castells A; Jover R
    Gut; 2012 Jun; 61(6):865-72. PubMed ID: 21868491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lynch syndrome among gynecologic oncology patients meeting Bethesda guidelines for screening.
    Walsh CS; Blum A; Walts A; Alsabeh R; Tran H; Koeffler HP; Karlan BY
    Gynecol Oncol; 2010 Mar; 116(3):516-21. PubMed ID: 20034658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of MLH1 methylation analysis in the clinical evaluation of Lynch Syndrome in women with endometrial cancer.
    Bruegl AS; Djordjevic B; Urbauer DL; Westin SN; Soliman PT; Lu KH; Luthra R; Broaddus RR
    Curr Pharm Des; 2014; 20(11):1655-63. PubMed ID: 23888949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular, pathologic, and clinical features of early-onset endometrial cancer: identifying presumptive Lynch syndrome patients.
    Walsh MD; Cummings MC; Buchanan DD; Dambacher WM; Arnold S; McKeone D; Byrnes R; Barker MA; Leggett BA; Gattas M; Jass JR; Spurdle AB; Young J; Obermair A
    Clin Cancer Res; 2008 Mar; 14(6):1692-700. PubMed ID: 18310315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.
    Capper D; Voigt A; Bozukova G; Ahadova A; Kickingereder P; von Deimling A; von Knebel Doeberitz M; Kloor M
    Int J Cancer; 2013 Oct; 133(7):1624-30. PubMed ID: 23553055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementation of tumor testing for lynch syndrome in endometrial cancers at a large academic medical center.
    Moline J; Mahdi H; Yang B; Biscotti C; Roma AA; Heald B; Rose PG; Michener C; Eng C
    Gynecol Oncol; 2013 Jul; 130(1):121-6. PubMed ID: 23612316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of Lynch syndrome among patients with upper urinary tract carcinoma in a Japanese hospital-based population.
    Ito T; Kono K; Eguchi H; Okazaki Y; Yamamoto G; Tachikawa T; Akagi K; Okada Y; Kawakami S; Morozumi M; Tamaru JI; Ishida H
    Jpn J Clin Oncol; 2020 Jan; 50(1):80-88. PubMed ID: 31665498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mismatch-repair deficiency, microsatellite instability, and lynch syndrome in ovarian cancer: A systematic review and meta-analysis.
    Mitric C; Salman L; Abrahamyan L; Kim SR; Pechlivanoglou P; Chan KKW; Gien LT; Ferguson SE
    Gynecol Oncol; 2023 Mar; 170():133-142. PubMed ID: 36682091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas.
    McConechy MK; Talhouk A; Li-Chang HH; Leung S; Huntsman DG; Gilks CB; McAlpine JN
    Gynecol Oncol; 2015 May; 137(2):306-10. PubMed ID: 25636458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Challenges Associated with Universal Screening for Lynch Syndrome-Associated Endometrial Cancer.
    Bruegl AS; Ring KL; Daniels M; Fellman BM; Urbauer DL; Broaddus RR
    Cancer Prev Res (Phila); 2017 Feb; 10(2):108-115. PubMed ID: 27965287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hereditary nonpolyposis colorectal cancer in endometrial cancer patients.
    Yoon SN; Ku JL; Shin YK; Kim KH; Choi JS; Jang EJ; Park HC; Kim DW; Kim MA; Kim WH; Lee TS; Kim JW; Park NH; Song YS; Kang SB; Lee HP; Jeong SY; Park JG
    Int J Cancer; 2008 Mar; 122(5):1077-81. PubMed ID: 17973265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microsatellite instability analysis in uterine cavity washings as a screening tool for endometrial cancer in Lynch syndrome.
    Bouquier J; Blons H; Narjoz C; Lécuru F; Laurent-Puig P; Bats AS
    Fam Cancer; 2011 Dec; 10(4):655-7. PubMed ID: 21822721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.